4DMT Secures Strategic Credit Facility for up to $200MM from Hercules Capital
4D Molecular Therapeutics, a late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, entered into a strategic credit facility agreement with Hercules Capital for up to $200 million. “Our...
Read moreDetails










